|
Surpass Indicated for the control of pain and inflammation associated with osteoarthritis in the hock, knee, fetlock and pastern joints in horses.
Surpass Dosage is a 5" ribbon applied with rubber gloves twice daily over the affected joint for up to 10 days. Rub Surpass thoroughly into the hair covering the joint until it disappears. One tube of Surpass will treat one horse for 10 days.
Surpass Direct contact with the skin should be avoided. Diclofenac Sodium 1%.
- SURPASS
- Rx
- Idexx Pharm.
- (1% diclofenac sodium)
- Topical Anti-Inflammatory Cream for Use in Horses
- CAUTION
- Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- DESCRIPTION
- SURPASS™ topical cream contains 1% diclofenac sodium. Diclofenac is a nonsteroidal anti-inflammatory drug of the phenylacetic acid class. The chemical name for diclofenac is sodium [o- (2,6-dichloroanilino)phenyl]acetate. The empirical formula is C14H10Cl2NNaO2 and the molecular weight is 318.13. SURPASS topical cream contains 1% diclofenac sodium in a base composed of Phospholipon 90H, propylene glycol, alcohol (5.94%), vitamin E acetate, benzethonium chloride and purified water in a liposomal formulation.
- INDICATIONS
- SURPASS topical cream is indicated for the control of pain and inflammation associated with osteoarthritis (OA) in tarsal, carpal, metacarpophalangeal, metatarsophalangeal and proximal interphalangeal (hock, knee, fetlock and pastern) joints in horses.
- DOSAGE AND ADMINISTRATION
- Always provide the Client Information Sheet with the prescription.
- Dosage: Apply a five-inch (5”) ribbon of SURPASS topical cream twice daily over the affected joint for up to ten days.
- Administration: Wear rubber gloves to prevent absorption into the hands. Rub the cream thoroughly into the hair covering the joint until it disappears.
- CONTRAINDICATIONS
- SURPASS topical cream is contraindicated in animals with known hypersensitivity to diclofenac.
- WARNINGS
- Not for horses intended for human consumption.
- User Safety: Keep out of reach of children. Not for human use. Consult a physician in case of accidental ingestion by humans.
- Wear gloves to prevent absorption into the hands. Direct contact with the skin should be avoided. If contact occurs, the skin should be washed immediately with soap and water.
- Animal Safety: For topical use in horses only. Owners should be advised to observe for signs of potential drug toxicity (see INFORMATION FOR OWNER OR PERSON TREATING ANIMAL and ADVERSE REACTIONS).
- PRECAUTIONS
- Exceeding the recommended dosage or treating multiple joints may increase plasma concentrations of diclofenac (see ANIMAL SAFETY). The systemic effects of excess diclofenac doses that exceed the recommended label amount and duration have not been evaluated.
- Horses should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data before and periodically during administration of any NSAID. Owners should be advised to observe for signs of potential drug toxicity (see INFORMATION FOR OWNER OR PERSON TREATING ANIMAL).
- Treatment with SURPASS should be terminated if signs such as inappetence, colic, fecal abnormalities, anemia or depression are observed.
- As a class, NSAIDs may be associated with gastrointestinal and renal toxicity. When NSAIDs inhibit prostaglandins that cause inflammation, they may also inhibit prostaglandins that maintain normal homeostatic function. These antiprostaglandin effects may result in clinically significant disease in patients with underlying or preexisting disease more often than in healthy patients. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular and/or hepatic dysfunction.
- Studies to determine the effect of SURPASS when administered concomitantly with other drugs have not been conducted. Since many NSAIDs possess the potential to induce gastric ulceration, concomitant use of SURPASS with any other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided. Drug compatibility should be monitored closely in patients receiving adjunctive therapy.
- The safety of SURPASS has not been investigated in breeding, pregnant or lactating horses, or in horses under one year of age.
- ADVERSE REACTIONS
- During the field study, one diclofenac-treated horse developed colic on day four of the study and responded to symptomatic treatment. One placebo-treated horse exhibited mildly jaundiced mucous membranes on day five. Adverse reactions during the safety study included a gastric ulcer in one horse that received 5.6X the recommended dosage, diarrhea and uterine discharge in one horse that received 2.8X the recommended dosage, and weight loss in four of the six horses in the 5.6X dosage group.
- To report suspected adverse reactions, to obtain a Material Safety Data Sheet or for technical assistance, call 1-800-374-8006.
- INFORMATION FOR OWNER OR PERSON TREATING ANIMAL
- Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with NSAID intolerance. Adverse reactions may include weight loss, colic, diarrhea, or icterus. Serious adverse reactions associated with this drug class can occur without warning and, in rare situations, result in death. Owners should be advised to discontinue NSAID therapy and contact their veterinarian immediately if signs of intolerance are observed. The majority of patients with drug-related adverse reactions recover when the signs are recognized, drug administration is stopped, and veterinary care is initiated.
- CLINICAL PHARMACOLOGY
- Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic properties. The mechanism of action of diclofenac, like other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity.
- EFFECTIVENESS
- In a controlled field study, 82 horses with osteoarthritis were treated with SURPASS (42 horses) or placebo (40 horses). Lameness examinations were performed in horses with osteoarthritis associated with the tarsal, carpal, metacarpophalangeal, metatarsophalangeal and proximal interphalangeal joints. Investigators were masked to treatment. Investigators and owners were instructed to apply the test article over the affected joint twice daily (BID) for five days. Actual doses received by individual horses were calculated using tube weight measurements. The mean dose applied during the study was 73 mg per application. Average lameness scores showed statistically significant improvement following treatment with SURPASS topical cream.
- One diclofenac-treated horse developed colic and responded to symptomatic treatment on day four of the study. Day five bloodwork for the horse that colicked showed decreases in RBC, Hb and HCT, with an increase in PMNs, compared to pretreatment values. One placebo-treated horse exhibited mildly jaundiced mucous membranes on day five. No other adverse reactions were noted during the study.
- ANIMAL SAFETY
- A controlled safety study was conducted with SURPASS topical cream. Four groups of six healthy adult horses received 0, 0.6, 1.7 or 2.8X the recommended daily dose for twenty-eight days. The daily dose was divided into two applications on day one of the study. For the remainder of the study, the entire daily dose was given at one time on 0, 1, 3 or 5 joints (tarsal, carpal, metacarpophalangeal, metatarsophalangeal, and proximal interphalangeal joints), depending on the dosage group. The control group of six horses was sham-dosed by rubbing the joints daily for twenty-eight days. An additional study group evaluated six horses that received 5.6X the recommended daily dose of SURPASS topical cream distributed over five joints on a single day. This dose group was observed for fourteen days without additional treatment.
- Clinical examinations, hematology, serum chemistry, synovial fluid analyses, gross necropsy and histopathology were performed. At necropsy, one horse in the 5.6X group had a glandular gastric ulcer. A horse in the 2.8X group had diarrhea and uterine discharge throughout the study. Four of the six horses in the 5.6X group lost weight during the study. Dose-dependent increases in diclofenac plasma concentrations were detected in horses in the 1.7X and 2.8X treatment groups.
- STORAGE INFORMATION
- Store at up to 25°C (77°F). Protect from freezing.
- HOW SUPPLIED
- SURPASS topical cream is white to pinkish-white and is packaged in 124-gram trilaminate tubes.
- NADA #141-186. Approved by FDA.
- SURPASS is a trademark of IDEXX Pharmaceuticals, Inc.
- Manufactured for:
- IDEXX Pharmaceuticals, Inc.
- Greensboro, North Carolina 27410 USA
- Manufactured under U.S. Patent No. 4,937,078.
- © 2004 IDEXX Pharmaceuticals, Inc. • 06-04369-01
|
Diclofenac 
